Use of suboptimal control arms in randomized clinical trials

In this observational study, Yichen Zhang and colleagues explore how comparator arms are used in randomized oncology trials registered in China.

Related Keywords

Peking , Beijing , China , Helsinki , Eteläuomen Läi , Finland , United States , Wanfang , Jiangxi , Chinese , Anitak Wagner , Huseyin Naci , National Medical Products Administration , Chinese Society Of Clinical Oncology , Drug Administration , University Health Science Center , Harvard Medical School , London School Of Economics , Oriented Oncology Drug Research , National Natural Science Foundation Of China , Oncologic Drugs Advisory Committee , China Center , National Comprehensive Cancer Network , China National Knowledge Infrastructure , Research On Equitable Access , Department Of Population Medicine , Harvard Pilgrim Health Care Institute , National Clinical Trial , Department Of Health , China Medicinal Product Administration Law , Us National Library Of Medicine , Drug Evaluation , Clinical Value Oriented Oncology Drug Research , Creative Commons Attribution License , Supporting Information , National Natural Science Foundation , Equitable Access , Rational Use , Peking University Health Science , Chinese Society , Clinical Oncology , United States Food , Information Disclosure Platform , Drug Clinical Studies , Wanfang Database , Preferred Reporting Items , Systematic Reviews , Breast Cancer , Gallbladder Carcinoma , Biliary Tract Cancer , Clinical Oncology Guideline , Under Part , Federal Regulations , Drugs Advisory Committee , Medicinal Product Administration Law , Data Safety Monitoring Board , Professor Huseyin Naci , Health Policy , London School , Political Science , Professor Anita , Population Medicine , Cancer Treatment , Randomized Controlled Trials , Oncology , Oncology Agents , Treatment Guidelines , Comparators , Clinical Trials ,